News 2026-09-15
Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001
Standardizing System Operations, Maintaining Certification Qualifications
Rigorous On-Site Audits, Ensuring Continuous Effectiveness
Covering an area of 34,000 m², Porton Chongqing Liangjiang Drug Product Manufacturing Site serves as an integrated end-to-end Drug Product CDMO platform under Porton Pharma Solutions. Adhering to US, EU, and Chinese GMP standards, the site is equipped with advanced international R&D equipment and analytical instruments. Backed by an experienced Drug Product team, it offers comprehensive drug lifecycle solutions for oral solid dosage forms, injection (lyophilized and liquid), and topical semi-solid dosage forms from early clinical stages to commercial supply, supporting OEB 1~4 products.
Deepening System Operations, Empowering Future Development
Successfully passing the ISO 14001 Environmental Management System and ISO 45001 Occupational Health and Safety Management System recertification audit not only provides strong recognition of the site's EHS performance, but also injects new momentum into its path toward high-quality development.
Fentian Zhou, General Manager of Porton Chongqing Liangjiang Drug Product Manufacturing Site and R&D Center, stated, "Achieving recertification for the dual management systems underscores our unwavering commitment to standardized management, safety, environmental protection, and sustainability. This not only enhances our operational resilience, but also provides our clients with robust quality assurance. We remain dedicated to supporting our clients throughout the entire drug lifecycle—from R&D to commercialization—with higher standards, more reliable services, and guaranteed supply security and compliance."
Standing at a new starting point, Porton will take this opportunity to further strengthen the operation of our dual management systems. Upholding high standards for greater environmental sustainability, safety and compliance, we will steadily advance our sustainable development and deliver greater value to our customers.

During the audit, the expert panel conducted a thorough and rigorous evaluation covering key areas such as environmental control, energy conservation, occupational health, operational safety, and risk prevention. Through document reviews, on-site inspections, and process tracing, the panel confirmed that the dual management systems of Porton Chongqing Liangjiang Drug Product Manufacturing Site are in line with standard requirements.
Others
More
News 2026-10-22
Simplifying Synthesis with Radical Cross-Coupling: Prof. Phil S. Baran of Scripps Research Lectures at Porton
The event was hosted by Dr. Yongli Zhong, CSO, and attended by Mr. Oliver Ju, Chairman and CEO; Mr. Yunxing Yin, VP and Head of the Small Molecule Platform, and more than 200 R&D and technical staff.

News 2026-10-16
Porton Achieves Third-Party Verification for Its First Commercial Product LCA and PCF Study
Conducted in accordance with ISO 14040:2006 and ISO 14044:2006 (Life Cycle Assessment) and ISO 14067:2018 (Product Carbon Footprint) standards, the study employs a cradle-to-gate system boundary, marking the formal extension of Porton's ESG management from the organizational level to the product level.